Analysts See $-0.18 EPS for MannKind Corporation (MNKD)

October 13, 2018 - By Vivian Park

MannKind Corporation (NASDAQ:MNKD) LogoInvestors sentiment is 1 in 2018 Q2. Its the same as in 2018Q1. It is the same, as 0 investors sold MannKind Corporation shares while 1 reduced holdings. only 1 funds opened positions while 0 raised stakes. 3,500 shares or 72.84% more from 2,025 shares in 2018Q1 were reported.
West Oak Limited Liability Corp holds 0% of its portfolio in MannKind Corporation (NASDAQ:MNKD) for 2,000 shares. Whittier Tru Company holds 0% of its portfolio in MannKind Corporation (NASDAQ:MNKD) for 1,500 shares.

Analysts expect MannKind Corporation (NASDAQ:MNKD) to report $-0.18 EPS on November, 6.They anticipate $0.13 EPS change or 41.94 % from last quarter’s $-0.31 EPS. After having $-0.16 EPS previously, MannKind Corporation’s analysts see 12.50 % EPS growth. The stock increased 5.26% or $0.08 during the last trading session, reaching $1.6. About 2.01M shares traded. MannKind Corporation (NASDAQ:MNKD) has declined 21.52% since October 14, 2017 and is downtrending. It has underperformed by 37.14% the S&P500.

MannKind Corporation (NASDAQ:MNKD) Ratings Coverage

Among 2 analysts covering MannKind (NASDAQ:MNKD), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. MannKind had 2 analyst reports since June 15, 2018 according to SRatingsIntel. H.C. Wainwright maintained MannKind Corporation (NASDAQ:MNKD) rating on Tuesday, June 26. H.C. Wainwright has “Buy” rating and $500 target.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. The company has market cap of $244.78 million. The Company’s approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. It currently has negative earnings.

More notable recent MannKind Corporation (NASDAQ:MNKD) news were published by: which released: “MannKind: Where The Truth, Honesty, And Candor Are Needed” on October 03, 2018, also with their article: “MannKind: Say It Ain’t So, Dr. Kendall!” published on September 20, 2018, published: “MannKind Corporation (MNKD) CEO Michael Castagna at Cantor Fitzgerald Global Healthcare Conference (Transcript)” on October 02, 2018. More interesting news about MannKind Corporation (NASDAQ:MNKD) were released by: and their article: “Implications For MannKind Regarding United Therapeutics Collaboration” published on September 24, 2018 as well as‘s news article titled: “MannKind: Afrezza Sales Close Out Q3 Modestly” with publication date: October 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.